Abstract
Adaptive resistance to immunotherapy in metastatic non-small cell lung cancer (mNSCLC) remains a challenge. Preclinical work suggests that constitutive interferon signaling promotes resistance to immune checkpoint blockade and blocking JAK1/2 later during the course of immunotherapy can potentially reverse this resistance. We present a phase II clinical trial of pembrolizumab and 6 weeks of itacitinib (INCB039110; JAK1 inhibitor) in mNSCLC patients with PDL expression ≥50% as first line therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
